<DOC>
	<DOCNO>NCT01264887</DOCNO>
	<brief_summary>The purpose trial characterization long term safety profile long-term dose requirement tapentadol PR ( prolonged release ) patient malignant tumor-related pain . In United States prolonged-release formulation also refer extended-release formulation .</brief_summary>
	<brief_title>Tapentadol Chronic Malignant Tumour Related Pain</brief_title>
	<detailed_description>The prevalence tumor-related pain high treatment chronic tumor-related pain remain challenge therapeutic problem . Participants directly enter KF5503/52 trial KF5503/15 trial ( i.e. , within 7 day Visit 8 KF5503/15 trial ) schedule : Transfer Visit , Open-label Treatment Period Follow-up Period . For participant gap 7 day less 24 week , full completion KF5503/15 trial entry KF5503/52 trial follow schedule : Enrollment Visit , Entry Visit assessment eligibility , Open-label Treatment Period Follow-up Period . This trial design offer patient chronic malignant tumor-related pain option continue treatment receive tapentadol prolong release ( PR ) . The protocol schedule visit every 28 day open-label treatment period . Unscheduled visit ( least unscheduled telephone call ) plan dose adjustment require . If visit possible time dose change , could do 7 day later . Unscheduled visit could also perform whenever consider necessary ( i.e. , evaluation adverse event ) .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Participants must sign Informed Consent Form . At least 18 year age . Male nonpregnant , nonlactating female subject . Sexually active woman must post menopausal , surgically sterile , practice effective method birth control entry throughout trial . Female participant childbearing potential must negative pregnancy test enrollment . Within 24 week either full completion completion doubleblind treatment period ( Visit 8 ) KF5503/15 trial perform participant moderate severe chronic malignant tumor relate pain . Participant , opinion investigator , expect continue overall positive benefit/risk ratio continue analgesic treatment within trial . Participant must willing take tapentadol prolong release ( PR ) throughout participation trial . History alcohol and/or drug abuse . The participant clinically significant disease cancer Investigator 's opinion may affect safety participant . Employees investigator trial center family member employee investigator . Known suspect able comply protocol use tapentadol prolong release ( PR ) . Concurrent participation another trial ( except participation KF5503/15 trial ) planning enrol another clinical trial course trial . Previous participation another trial end KF5503/15 enrollment current trial , KF5503/52 . History seizure disorder , epilepsy , traumatic brain injury , stroke transient ischemic attack . Known history and/or presence cerebral tumor metastasis . Rapidly escalate pain pain uncontrolled therapy previously treat maximum dose level Investigational Medicinal Product . Participant take prohibit concomitant medication . Uncontrolled hypertension . Known moderate severe hepatic impairment . Known severe renal impairment . Clinically relevant history hypersensitivity , allergy , contraindication tapentadol excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>analgesia</keyword>
	<keyword>analgesic</keyword>
	<keyword>chronic pain</keyword>
	<keyword>tumour relate pain</keyword>
	<keyword>chronic malignant tumor-related pain</keyword>
</DOC>